中国科学院机构知识库网格系统: 检索

浏览/检索结果: 共9条，第1-9条

帮助

条数/页：排序方式：
	YCH1899, a Highly Effective Phthalazin-1(2H)-one Derivative That Overcomes Resistance to Prior PARP Inhibitors 期刊论文 OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2023, 页码: 20 作者: Sun, Yuting; Yang, Hui; Yuan, Jiaqi; Wang, Limin; Song, Shanshan \| 收藏 \| 浏览/下载：10/0 \| 提交时间：2023/10/17
	Design, synthesis and pharmacological evaluation of new PARP1 inhibitors by merging pharmacophores of olaparib and the natural product alantolactone 期刊论文 OAI收割 EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 卷号: 240, 页码: 114574 作者: Kayumov, Muzaffar; Jia, Li; Pardaev, Azizbek; Song, Shan-Shan; Mirzaakhmedov, Sharafitdin \| 收藏 \| 浏览/下载：13/0 \| 提交时间：2024/03/21 PARP1 Olaparib Alantolactone Syntheticlethality BRCA1/2mutant
	Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold 期刊论文 OAI收割 JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 64, 期号: 9, 页码: 6161-6178 作者: Xiong, Chaodong; Zhou, Lina; Tan, Jing; Song, Shanshan; Bao, Xubin \| 收藏 \| 浏览/下载：19/0 \| 提交时间：2021/08/17
	SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文 OAI收割 CANCER SCIENCE, 2019, 页码: 11 作者: Tong, Mengya; Gao, Mingzhao; Xu, Yongping; Fu, Li; Li, Yun \| 收藏 \| 浏览/下载：49/0 \| 提交时间：2020/07/01 AZD9291 c-Met ADC c-Met overexpression resistance SHR-A1403
	Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants 期刊论文 OAI收割 CANCER SCIENCE, 2019, 页码: 9 作者: Gao, Mingzhao; Zhu, Hongmei; Fu, Li; Li, Yun; Bao, Xubin \| 收藏 \| 浏览/下载：28/0 \| 提交时间：2020/07/01 AG-221 IDH2 leukemia R140Q R172K
	Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models 期刊论文 OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 4, 页码: 1420-1430 作者: Long, Fei; He, Ye; Fu, Haoyu; Li, Yun; Bao, Xubin \| 收藏 \| 浏览/下载：23/0 \| 提交时间：2020/07/01 breast cancer CDK 4/6 drug resistance palbociclib SHR6390
	Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文 OAI收割 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者: Wang, Lei; Yang, Changyong; Xie, Chengying; Jiang, Jiahua; Gao, Mingzhao \| 收藏 \| 浏览/下载：21/0 \| 提交时间：2020/07/01 antitumor activity fluzoparib pharmacokinetics poly(ADP-ribose) polymerase toxicity
	Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist 期刊论文 OAI收割 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 卷号: 22, 期号: 11, 页码: 5367-5377 作者: Xie, Chengying; Zhao, Huajun; Bao, Xubin; Fu, Haoyu; Lou, Liguang \| 收藏 \| 浏览/下载：34/0 \| 提交时间：2019/01/08 eltrombopag hetrombopag hollow-fibre assay thrombopoietin thrombopoietin receptor
	Combined inhibition of PI3K delta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia 期刊论文 OAI收割 CANCER LETTERS, 2018, 卷号: 420, 页码: 49-59 作者: He, Ye; Sun, Liping; Xu, Yongping; Fu, Li; Li, Yun \| 收藏 \| 浏览/下载：34/0 \| 提交时间：2019/01/08 Acute myeloid leukemia FLT3 PI3K delta CAL101 Synergistic effect